This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Servier challenge over lower court ruling on blood-pressure drug UK suit heard by Supreme Court

( June 9, 2020, 22:22 GMT | Official Statement) -- MLex Summary: Servier's challenge over a lower appeal-court ruling last year that dismissed its bid to limit the scope of an upcoming UK damages lawsuit by health authorities over its blood-pressure drug has been heard by the Supreme Court. The French drugmaker has argued that findings of fact in an judgment by the EU General Court should have a binding effect on the UK proceedings. The dispute stems from 2014, when Servier and five makers of generic drugs were fined 428 million euros by the European Commission for restricting the supply of generic versions of perindopril, marketed under the brand name Coversyl in the UK. The UK government alleges that Servier’s pay-for-delay deals meant it abused its dominant market position from 2001 to 2007 to stifle competition. Statement follows below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections